Ranisan

Quick links to important sections

Ranisan

Selected form

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ranisan

Property Description
Active ingredient Ranitidine Hydrochloride
Forms Tablet, Effervescent Tablet, Injection, Syrup
Pharmacological class Histamine H₂-receptor antagonist (H₂ blocker)
General purpose Reduces stomach acid and pepsin secretion
Origin Synthetic chemical entity

What is Ranisan, and What Kind of Drug is It?

Ranisan is a synthetic pharmaceutical product whose active ingredient is Ranitidine Hydrochloride, a small-molecule compound. It is formally classified as a Histamine H₂-receptor antagonist (or H₂ blocker), a drug class used for its ability to regulate gastric function by acting on specific receptors in the stomach lining. This distinct classification indicates that the medicine operates via a systemic, receptor-blocking mechanism, setting it apart from simple, topical acid neutralizers. As a therapy for acid-related conditions, it provides control over acid output.


Composition and Available Forms of Ranisan

Ranisan is supplied as a single-ingredient product, containing only Ranitidine Hydrochloride alongside necessary inert excipients to ensure stability and proper release. The product is often distinguished by its diverse dosage forms, including traditional tablets (often film-coated), effervescent tablets, oral syrups, and specialized sterile solutions for injection. This flexibility, particularly the availability of formulations for both oral and parenteral routes of administration, ensures that the medicine can be used in various contexts, from routine patient management to more acute hospital settings.


What is the General Purpose of Taking Ranisan?

The general purpose of using Ranisan is to achieve a significant and prolonged reduction in the secretion of gastric acid and pepsin within the stomach. This reduction occurs because the drug acts to block the primary signals that trigger acid release from the parietal cells. This fundamental action helps to mitigate the corrosive effects of excessive gastric fluids. This overall benefit is typically sought in scenarios where the gastrointestinal lining requires relief or healing from irritation, such as when a patient experiences acid reflux symptoms that need controlled suppression. By lowering the hydrogen ion concentration, Ranisan aids in creating a less hostile environment in the upper digestive tract.

Regulatory References

  1. clinically recognized for its ability to regulate gastric function

What side effects are possible with Ranisan?

Possible Side Effects and Safety Information

The safety profile for Ranitidine Hydrochloride, the active ingredient in Ranisan, is based on official regulatory classifications that group reactions by frequency (uncommon, rare, very rare) and affected organ system. This categorization establishes a systematic risk framework for all documented adverse events.

Frequency-Classified Adverse Reactions

The most frequently observed adverse reactions are classified as uncommon and generally relate to gastrointestinal discomfort, including abdominal pain, constipation, and nausea. These symptoms are often noted in regulatory documents as showing improvement during continued treatment.

Rare reactions documented include transient changes in liver function tests, hypersensitivity reactions (such as rash), and bronchospasm.

Serious Adverse Reactions and Safety Constraints

The most serious, though very rare, reactions involve multiple organ systems. These include severe hepatobiliary disorders like hepatitis (sometimes leading to hepatic failure), acute pancreatitis, certain blood disorders (e.g., agranulocytosis), and anaphylactic shock. The severe hypersensitivity reaction of anaphylactic shock has been reported even following a single exposure.

Population-Specific and General Constraints

The official label contains specific safety notes for certain patient populations. Severely ill and elderly patients have a documented increased risk for reversible central nervous system effects, such as mental confusion and hallucinations. Caution is also required for individuals with renal impairment due to the drug's primary route of excretion.

A critical safety restriction noted in official labeling is that symptomatic improvement does not exclude the presence of gastric malignancy (known as malignancy masking). Furthermore, the safety profile has been subject to specific regulatory review due to the potential presence of the N-nitrosodimethylamine (NDMA) impurity in the Ranitidine molecule.

Overdose and Emergency Response

Overdose and Regulatory Safety Risk

Unlike traditional pharmacological overdose, the primary public health concern for Ranisan (ranitidine) centered on the long-term risk associated with an impurity, N-Nitrosodimethylamine (NDMA), a probable human carcinogen. Regulatory agencies, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), determined that NDMA levels in some products could increase over time and when stored at higher than room temperatures, potentially exposing consumers to unacceptable levels.

Overdose Context Official Regulatory Finding
Acute Overdose Symptoms General overdose reports for this class of medicine may include confusion, drowsiness, slurred speech, rapid or slow heartbeat, and agitation. Always call a Poison Control Center or seek emergency medical help immediately if over-ingestion is suspected.
Safety Risk Exposure Sustained exposure to the NDMA impurity above the acceptable daily intake limit of 96 nanograms per day.
Required Action Regulatory authorities requested the complete withdrawal of all prescription and over-the-counter ranitidine products from the market.

When to Seek Immediate Medical Help

  • Acute Overdose: If a person takes more than the prescribed or recommended amount, or any amount of a product that has been recalled, call a Poison Control Center right away or go to the nearest emergency room.
  • Existing Prescription Use: Patients who were taking prescription ranitidine were advised to speak with their healthcare professional about alternative treatment options before stopping the medicine, as abruptly discontinuing a drug without guidance can be unsafe.

Therapeutic Uses of Ranisan

What Ranisan Treats: Main Uses and Benefits

Ranisan is commonly used across conditions presenting with symptoms related to inflammatory or irritative states in the upper gastrointestinal tract. It helps address symptom clusters associated with conditions like active duodenal and gastric ulcers, Gastroesophageal Reflux Disease (GERD), erosive esophagitis, and pathological hypersecretory conditions such as Zollinger-Ellison syndrome. The medication generally provides supportive symptomatic relief that helps patients cope with difficult episodes, contributing to comfort during periods of heightened symptoms. It is also relevant in clinical settings that involve acute or unstable symptom patterns, where it is used for supportive symptom management. This includes situations involving heightened systemic burden, or when the medicine is applied to manage acute symptoms in a clinical environment. “It assists with maintaining functional stability when acid-related discomfort interferes with routine activities.”


Quick Fact: Relief for Heartburn and Acid Discomfort

Eligibility and Restrictions for Use

Ranisan (Ranitidine Hydrochloride) eligibility is strictly defined by regulatory bodies based on population characteristics and pre-existing conditions. These rules determine who is permitted to use the medicine under standard labeled conditions and who is absolutely prohibited from use.

Contraindicated Populations

Use of Ranisan is contraindicated and must be avoided in patients with known hypersensitivity to ranitidine or any of its components. It is also contraindicated for patients with a history of acute porphyria, as the medicine may precipitate acute attacks.

Populations Requiring Restricted or Conditional Use

Population Group Regulatory Status
Severe Renal Impairment Restricted Use: Requires medical supervision due to the risk of drug accumulation.
Undiagnosed Gastric Ulcer Conditional Use: Gastric malignancy must be formally excluded prior to treatment, as Ranisan may mask symptoms.
Pregnancy / Lactation Not Recommended: Use is generally restricted and should only occur if deemed essential by a healthcare provider.
Neonates (< 1 month) Use Not Established: Safety and efficacy have not been established in this age group.

In older adult patients, use is generally permitted, but the official label recommends consideration of potential age-related decline in renal function.

What should I know about interactions with other medicines?

Ranisan Interactions with other medicines and products

Interactions with Ranisan (ranitidine) primarily occur through two distinct mechanisms: the reduction of gastric acidity and the alteration of drug metabolism or excretion.

Interaction Mechanisms and Consequences

  • Altered Gastric pH: As an H2-receptor antagonist, Ranisan raises the pH of the stomach. This effect can reduce the absorption and effectiveness of certain medicines that require an acidic environment to dissolve properly, such as azole antifungals (e.g., ketoconazole, itraconazole) and some anti-HIV agents (e.g., atazanavir, delavirdine). Vitamin B12 absorption from food may also be reduced with long-term use.
  • Metabolic and Excretory Effects: Ranitidine may affect the systemic levels of other drugs through two pathways. It can inhibit certain cytochrome P-450 enzymes in the liver (though typically less potent than cimetidine), leading to increased plasma concentrations of drugs like warfarin, theophylline, and midazolam. Additionally, it can compete with drugs like procainamide for clearance via the renal tubular secretion system, potentially leading to higher blood levels of these co-administered medicines.

Specific Interactions

Close clinical monitoring is generally recommended when Ranisan is used concurrently with medicines that have a narrow therapeutic range, such as warfarin (due to risk of altered prothrombin time) or procainamide. Co-administration with clopidogrel may be restricted due to the potential for reduced antiplatelet efficacy. Antacids may reduce Ranisan's own absorption if taken concurrently, often requiring spaced administration (e.g., 1–2 hours apart).

Mechanism of Action

Mechanism of Action: H2 Receptor Antagonism

Ranisan (ranitidine) exerts its action as a highly selective, competitive antagonist at the Histamine H2 receptors found on the basolateral membrane of the gastric parietal cells. By binding to this target, the molecule prevents the endogenous chemical messenger, histamine, from initiating the acid-secretory cascade.

This H2 receptor blockade disrupts the intracellular signaling cascade by preventing the histamine-mediated stimulation of adenylate cyclase. Consequently, the intracellular concentration of cyclic AMP (cAMP) is reduced, which limits the activation and mobilization of the final acid-secreting enzyme, the H^+/ K^+-ATPase (Proton Pump).

This molecular interference results in a significant reduction of hydrogen ion ( H^+) secretion into the stomach lumen. The mechanism is characterized by a high degree of suppression of continuous basal acid output, thereby leading to an increase in gastric pH and secondarily lowering the activity of the digestive enzyme pepsin. The mechanism is stimulus-specific, meaning acid secretion driven by other secretagogues is only partially modulated. Tachyphylaxis is a biological constraint observed in this pathway engagement.

Dosage and Administration Information

Ranisan is administered via the oral route, available as tablets, syrups, and effervescent forms, or through the parenteral route as a sterile solution for intravenous (IV) or intramuscular (IM) injection. The choice of route depends on the care setting; parenteral use is generally reserved for hospitalized patients who cannot take the medication orally.

In typical clinical application, standard adult dosing involves taking 150 mg twice daily or an alternative regimen of 300 mg once daily at bedtime for acute treatment. Once the condition stabilizes, long-term maintenance therapy often employs a reduced dose of 150 mg once daily at bedtime. The duration of acute treatment is usually between 4 and 8 weeks, with maintenance use extending for up to one year.

Administration follows specific procedural rules. Effervescent tablets must be fully dissolved in water before consumption. Intravenous doses, such as the standard 50 mg every 6 to 8 hours, require dilution and must be injected slowly over a period of at least five minutes to ensure proper delivery. Furthermore, a dosage reduction is specified for patients with renal impairment (creatinine clearance < 50 mL/min), often adjusted to 150 mg once daily at night to prevent accumulation. The timing of oral doses is not required to be synchronized with meals.

Recent Clinical Evidence

Research evidence / Overview of Studies for Ranisan

Evidence for Use in Active Duodenal and Benign Gastric Ulcers

Ranisan was studied for its role in the presentation of active ulcers in the stomach lining and the upper part of the small intestine (duodenal ulcers). The primary research methods used were controlled studies, known as Randomized Controlled Trials (RCTs). Researchers focused on the ulcer healing rate via endoscopic confirmation and examined patient-reported outcomes, such as tracking how often patients reported symptoms of discomfort during the day and night and how frequently they needed to use other antacid medications. Studies reported how symptoms evolved in the observed populations over the short term related to these irritative states.

Evidence for Use in Acid Reflux Disease (GERD) and Erosive Esophagitis

For conditions like Gastroesophageal Reflux Disease (GERD) and Erosive Esophagitis, Ranisan was evaluated in various research settings. RCTs were frequently applied in research contexts involving fluctuating or unstable symptoms of acid reflux. Primary research focused on patient-reported outcomes describing perceived discomfort, specifically the frequency of heartburn, and endoscopic healing rate. Certainty remains low when considering its performance against some newer medications, and long-term effects are not fully established regarding the maintenance of symptom relief and observation for esophagitis over periods longer than one year.

Long-Term Study Follow-up and Maintenance Data

A dedicated body of research was evaluated in studies tracking patients over defined, extended time intervals. This research focuses on the maintenance of observed patterns after a period of initial observation. For instance, some trials monitored patterns of recurrence in previously observed duodenal ulcers or esophagitis lesions over six months to a year. Follow-up durations were limited primarily to one year or less in the most robust controlled trials, and there is limited information for long-term outcomes beyond these initial periods.

What is Still Uncertain About Ranisan Research

The available evidence base contains gaps or limitations. Comparative evidence against the latest classes of acid-reducing drugs remains insufficient in contemporary head-to-head trials for some indications. Data for certain groups remain insufficient, especially for those with rare or complex health profiles. The findings describe group patterns, not personal outcomes, and research provides context but not individual predictions about how any single person might respond.

Key Studies & References

  1. Comparison of Hypoallergenic Diet vs. Ranitidine in Treatment of Gastroesophageal Reflux Disease of Infants: A Randomized Clinical Trial

Frequently Asked Questions (FAQ)

Common questions about Ranisan (FAQ)

Q: What is Ranisan most commonly prescribed for?

According to official product information, Ranisan is commonly prescribed for the treatment and prevention of ulcers in the stomach and the upper part of the small intestine (duodenal ulcers). It is also described for managing conditions caused by excess stomach acid, such as Gastroesophageal Reflux Disease (GERD) and erosive esophagitis.


Q: How long does it usually take for Ranisan to start working?

Studies and official information indicate that Ranisan usually begins to reduce the production of stomach acid within about an hour of the first dose. This initial effect reflects the drug's interaction with its target in the body to begin acid reduction.


Q: Does Ranisan take time to build up in the body before being effective?

Official product information describes the acid-reducing effect of Ranisan as occurring shortly after the first dose is taken. Therefore, it is not described as a medication that requires a cumulative 'build-up' phase in the body before it can begin working effectively.


Q: Is it known if Ranisan causes changes in mood?

Official regulatory documents report that very rare central nervous system (CNS) effects have been noted, primarily in severely ill and elderly patients. These effects have included descriptions of mental confusion, depression, and hallucinations, which are related to mood and mental state, but are not common occurrences.


Q: Can Ranisan cause a person to feel unusually tired or sleepy?

Regulatory documents do not typically list general tiredness or sleepiness as a common side effect of Ranisan. However, the official label does mention very rare central nervous system effects, such as dizziness and mental confusion, which may affect a person’s overall sense of alertness.


Q: Does Ranisan interact with supplements or vitamins?

Official product information notes that using Ranisan for long periods may be associated with a reduction in the body's ability to absorb Vitamin B12 from food. Regulatory sources generally do not list interactions with other specific vitamins or supplements.


Q: Is it acceptable to consume alcohol while taking Ranisan?

While official documents do not list alcohol as strictly prohibited, they often caution that alcohol consumption can increase the production of stomach acid. This increase in acid may work against the intended effect of Ranisan, which is to reduce acid.


Q: Can people with pre-existing liver issues take Ranisan?

Official documents state that caution is necessary when Ranisan is administered to patients who have pre-existing liver impairment. The drug has been associated with very rare reports of severe liver-related issues, such as hepatitis.


Q: Is Ranisan generally suitable for the elderly population?

Official information permits the use of Ranisan in older adults. However, the official label notes that caution is a consideration, largely due to an increased potential for central nervous system effects in the severely ill and elderly, and because age can affect kidney function.


Q: Has Ranisan been studied and approved for use in children?

Official regulatory labels define specific indications and dosing instructions for children and adolescents (e.g., 3 to 18 years old) for certain conditions like Gastroesophageal Reflux Disease (GERD). However, use is explicitly stated as not established in the youngest age group of neonates (infants under one month old).


Q: How long does Ranisan typically stay in the body after the last dose is taken?

The time a medicine stays in the body is often measured by its half-life, which for Ranisan is generally described as being around 2 to 3 hours in individuals with normal kidney function. The body primarily clears the medicine through the kidneys.


Q: What are the listed warnings about using Ranisan if a person has certain heart conditions?

Official documents include a warning for patients with predisposing factors for cardiac rhythm disturbances. The label notes that rare cases of bradycardia, which is a slower-than-normal heart rate, have been reported, particularly when the medicine is given quickly by injection (intravenously).


Q: Can Ranisan affect the results of common blood or lab tests?

Official documentation reports that Ranisan use has been associated with transient and reversible changes in liver function tests. There have also been very rare reports of changes to certain blood counts, such as leucopenia, documented in the official safety information.


Q: Does the manufacturer's information for Ranisan list any necessary monitoring?

The official label contains a specific warning that the presence of gastric malignancy (stomach cancer) must be ruled out before starting treatment with Ranisan. This is because the drug's effect of relieving symptoms may inadvertently mask the presence of a serious underlying condition.


Q: Is Ranisan a controlled or scheduled substance?

The active ingredient in Ranisan, ranitidine, is not classified as a controlled substance by major governmental drug enforcement or scheduling authorities. This means it is not subject to the strict regulatory controls of scheduled medications.


Q: What is the general duration of action for a single dose of Ranisan?

Official studies of Ranisan indicate that a single dose can typically provide a significant reduction in the secretion of stomach acid for approximately 8 to 12 hours. This duration reflects the period during which the drug provides significant inhibition of acid secretion.


Q: What does current medical literature say about the long-term safety profile of Ranisan?

Studies that followed patients in robust controlled trials for Ranisan have been limited primarily to a duration of one year or less. Separately, long-term use is associated with a known risk of reduced absorption of Vitamin B12 from food.

How should Ranisan be stored and disposed of?

How to Store and Dispose of Ranitidine (Ranisan) Products

The following instructions are based on official regulatory labeling to maintain product integrity and ensure proper disposal.

Storage Requirements

Condition Requirement (Official Labeling)
Temperature Store tablets at controlled room temperature, 20 C to 25 C (68 F to 77 F); do not freeze or expose to excessive heat.
Protection Must be kept in a tight, light-resistant container and protected from humidity; the cap must be replaced securely after each use.
Prepared Solutions Reconstituted oral solutions must be stored under refrigerated conditions (2 C to 8 C) and are stable for approximately eight weeks.
Child Safety The medicine must be kept out of the sight and reach of children at all times.

Disposal Instructions

Following regulatory market withdrawal requests, consumers are advised to stop taking the product and dispose of it properly. Disposal should involve mixing the pills or liquid with an unappealing substance (like dirt or coffee grounds), placing the mixture in a sealed plastic bag, and then discarding it in household trash. Medicines should not be flushed down the toilet or returned to take-back locations, as per specific guidance related to the product's withdrawal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ranisan found in:

A-Z Index: